Nanotechnology Now - Press Release: BIO InvestorForum 2007 Presenter Profiles

Home > Press > BIO InvestorForum 2007 Presenter Profiles

Abstract:
)--BIO InvestorForum 2007 takes place Oct. 9 - 11, 2007 at the Palace Hotel in San Francisco. Listed below are BIO InvestorForum presenter profiles. For in-depth information about the event, visit http://investorforum.bio.org/opencms/bif/2007/index.jsp .

BIO InvestorForum 2007 Presenter Profiles

SAN FRANCISCO, CA | Posted on October 8th, 2007

Business Wire is the official news wire for the BIO InvestorForum. Breaking news releases and photos are available at http://www.tradeshownews.com , Business Wire's trade show, conference, and event news resource.
Company: Affymax, Inc.
Ticker Symbol & Exchange: affy
Investor Relations Contact: Sylvia Wheeler
Investor Relations Contact Phone: (650) 812-8861
Web: http://www.affymax.com
Date of Presentation: 10-Oct-07
Affymax is a biopharmaceutical company creating novel approaches for improving patient care for serious and life-threatening conditions in kidney disease and cancer. The company is building a pipeline of drugs against clinically validated targets that Affymax believes will demonstrate significant advantages over currently marketed protein products.

Hematide™, the company's first product candidate to enter the clinic, is a novel peptide-based drug designed to stimulate the production of red blood cells. It is currently entering Phase 3 clinical trials for the treatment of anemia associated with chronic renal failure and is in Phase 2 clinical trials for the treatment of anemia in cancer patients.

Company: Alfacell Corporation
Ticker Symbol & Exchange: ACEL (NASDAQ)
Investor Relations Contact: Andreas Marathovouniotis
Investor Relations Contact Phone: Russo Partners, LLC; 212-845-4253
Web: http://www.alfacell.com
Date of Presentation: Thursday, October 11, 2007
Alfacell Corporation is the first company to advance a biopharmaceutical product candidate that works in a manner similar to RNA interference (RNAi) through late-stage clinical trials. The product candidate, ONCONASE®, is an RNase that overcomes the challenges of targeting RNA for therapeutic purposes while enabling the development of a new class of targeted therapies for cancer and other life-threatening diseases. In addition to an ongoing Phase IIIb study in malignant mesothelioma, Alfacell is conducting a Phase I/II trial of ONCONASE in non-small cell lung cancer (NSCLC) and other solid tumors.

Company: Antares Pharma, Inc.
Ticker Symbol & Exchange: AIS, AMEX
Investor Relations Contact: Stephanie M. Baldwin
Investor Relations Contact Phone: 609.359.3032
Web: http://www.antarespharma.com
Date of Presentation: 10.11.07 @ 3:00 pm

Antares is committed to developing and commercializing novel therapeutic products utilizing our advanced drug delivery systems which include: the ATD™ gel system, the Vibex™ and Vision® injection systems and our Easy Tec™ oral fast-melt technology. We are a product focused company that has developed three platforms, two of which now include FDA approved products. Our products are engineered to improve safety and efficacy profiles by minimizing dosing and reducing side effects. Our therapeutic focus areas are: CNS / pain and women's health / urology.

Company: Argenes, Inc.
Investor Relations Contact: Naoki Kobayashi
Investor Relations Contact Phone: 81-3-3580-1705
Web: http://www.argenes.co.jp
Date of Presentation: 11-Oct
Argenes is a leading bio-venture focused on the development of novel therapeutics for the treatment of musculoskeletal diseases including rheumatoid arthritis, fibromyalgia and other arthritis. By the strategic alliances with pharmaceuticals including Santen, Nippon Zoki and possible future partners worldwide, scientific and medical networks led by St. Marianna University School of Medicine and the core technology for manufacturing of biopharmaceuticals including monoclonal antibodies, Argenes developments novel therapeutics to have proof of concept and to market them to satisfy unmet medical needs.

Company: AVICENA GROUP,INC.
Ticker Symbol & Exchange: (OTCBB: AVGO)
Investor Relations Contact: Sara Ephraim, The Ruth Group
Investor Relations Contact Phone: 646-536-7002
Web: http://www.avicenagroup.com
Date of Presentation: October 9-11, 2007@ 10:30 AM
Avicena Group, Inc. is a Palo Alto, California based late stage biotechnology company that develops central nervous system therapeutics for neurodegenerative diseases. The company's core technologies, supported by a robust IP portfolio, have broad applications in both pharmaceuticals and dermaceuticals. Avicena's pharmaceutical program centers on rare neurological disorders (orphan diseases). The company is currently analyzing data from its Phase IIb/III trial in ALS. Near term, Avicena intends to initiate a Phase III trial in Huntington's disease to accompany the ongoing NIH Phase III trial in Parkinson's disease. Avicena's science is well established and its products are safe and well tolerated. Unlike traditional biotechnology companies, Avicena's clinical programs are largely funded by government and non-profit organizations.

Company: Bayhill Therapeutics, Inc.
Investor Relations Contact: Fred Kurland
Investor Relations Contact Phone: (650) 320-2808
Web: http://www.Bayhilltherapeutics.com
Date of Presentation: Oct. 10, 2007
Bayhill Therapeutics Inc. is a clinical-stage biotechnology company focused on developing and commercializing therapeutics that fundamentally alter the way autoimmune diseases are treated. The company has developed two therapeutic platforms with broad applicability to a range of autoimmune diseases. Bayhill's BHT-DNA autoimmune vaccine is designed to eliminate disease-causing cells without effecting normal protective immune system cells. The company recently showed proof of concept in a Phase IIb clinical trial evaluating its lead product candidate, BHT - 3009 for the treatment of multiple sclerosis. Another of the company's product candidates, BHT - 3021 is being studied in a Phase I/II trial for autoimmune diabetes. Bayhill's second therapeutic is an oligonucleotide in preclinical development for systemic lupus erythematosus.

Company: BioMimetic Therapeutics, Inc.
Ticker Symbol & Exchange: NASDAQ: BMTI
Investor Relations Contact: Kearstin Patterson
Investor Relations Contact Phone: 615-236-4419
Web: http://www.biomimetics.com
Date of Presentation: October 9; 3:45
BioMimetic Therapeutics, Inc. is an emerging leader in the development and commercialization of drug-device combination products for the repair of orthopedic injuries to bone, cartilage, ligaments and tendons. BioMimetic's suite of products and product candidates combine recombinant protein therapeutics with tissue specific scaffolds, actively stimulating tissue healing and regeneration. BioMimetic believes its biologically-enhanced orthopedic therapies can improve the treatment options and quality of life for millions of patients suffering injuries or deterioration of the bones, cartilage (joints), ligaments and tendons.

Company: BioSante Pharmaceuticals, Inc.
Ticker Symbol & Exchange: BPA: Amex
Investor Relations Contact: Phillip Donenberg
Investor Relations Contact Phone: 847-478-0500 x100
Web: http://www.biosantepharma.com
Date of Presentation: 10/10/2007
BioSante is developing a pipeline of hormone therapy products. BioSante's lead products include Elestrin™ (estradiol gel) developed through FDA approval by BioSante indicated for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, marketed in the U.S. by Bradley Pharmaceuticals, Inc., BioSante's licensee, and LibiGel® (transdermal testosterone gel) in Phase III clinical development by BioSante for the treatment of female sexual dysfunction (FSD); Bio-T-Gel™, for male hypogonadism, and an oral contraceptive in Phase II. The company also is developing its calcium phosphate nanotechnology (CaP) for novel vaccines, delivering drugs via alternative routes of administration and for aesthetic medicine.

Company: CELLECTIS
Ticker Symbol & Exchange: ALCLS; NYSE Euronext
Investor Relations Contact: Marc le Bozec, CFO
Investor Relations Contact Phone: 33(1) 41 83 99 00
Web: http://www.cellectis.com
Date of Presentation: October 11, 2007 - 10:30am
Cellectis is a world-leading company in genome engineering and genome surgery.

The company is focused on developing and producing custom meganucleuses for in vivo DNA surgery and also provides new tools for rational reverse genetics and targeted recombination. Cellectis' products induce unique, site-directed, double-strand DNA breaks in any living cell and can be used in a wide range of biotechnological and therapeutic applications. To date Cellectis has entered into more than 45 deals with major players in the pharma, biotech and agrobiotech industries.

Cellectis has successfully listed on the Alternext market of NYSE-Euronext and raised 24,4 million euros

Company: Cell Genesys, Inc.
Ticker Symbol & Exchange: Nasdaq: CEGE
Investor Relations Contact: Susan Ferris
Investor Relations Contact Phone: 650-266-2918
Web: http://www.cellgenesys.com
Date of Presentation: 10-Oct-07
Cell Genesys, headquartered in South San Francisco, is focused on the development and commercialization of novel biological therapies for patients with cancer. The company is currently pursuing two clinical stage product platforms--GVAX™ cancer immunotherapies and oncolytic virus therapies. Ongoing clinical trials include Phase 3 trials of GVAX immunotherapy for prostate cancer, Phase 2 trials of GVAX immunotherapies for pancreatic cancer and for leukemia, and a Phase 1 trial of CG0070 oncolytic virus therapy for bladder cancer. Cell Genesys continues to hold an equity interest in its former subsidiary, Ceregene, Inc., which is developing gene therapies for neurodegenerative disorders.

Company: Ceregene, Inc.
Investor Relations Contact: Jeffrey M. Ostrove, Ph.D.
Investor Relations Contact Phone: 858-458-8808
Web: http://www.ceregene.com
Date of Presentation: 10/10/07, 2:45pm PT
Ceregene is a San Diego-based biotechnology company focused on the delivery of nervous system growth factors to treat neurodegenerative disorders using gene delivery. Ceregene's clinical programs include CERE-110, an AAV2 based vector expressing nerve growth factor that is currently in Phase 1/2 studies for the treatment of Alzheimer's disease, and CERE-120 (AAV2-Neurturin) currently in a controlled Phase 2 study for Parkinson's disease. CERE-130 and CERE-140 are in preclinical development for ALS and ocular disorders, respectively. Ceregene's investors include Alta Partners, MPM Capital, Investor Growth Capital and Cell Genesys (Nasdaq: CEGE), as well as Hamilton BioVentures and California Technology Partners.

Company: Codexis
Investor Relations Contact: Robert Breuil
Investor Relations Contact Phone: 650-298-5372
Web: http://www.codexis.com
Date of Presentation: 10-Oct
Codexis, Inc. is a leading developer of biocatalytic process technologies that can substantially reduce the cost of manufacturing across a broad range of industries. Codexis' proprietary directed evolution technologies enable novel solutions for efficient, cost-effective and environmentally friendly processes for pharmaceutical, energy and industrial chemical applications. In 2006, Codexis was recognized by the U.S. Environmental Protection Agency with a Presidential Green Chemistry Challenge Award for developing an environmentally friendly, low-cost alternative manufacturing process.

Company: Critical Therapeutics, Inc.
Ticker Symbol & Exchange: CRTX: Nasdaq
Investor Relations Contact: Linda Lennox
Investor Relations Contact Phone: (781) 402-5708
Web: http://www.crtx.com
Date of Presentation: 10/11/07 at 3:30PM (PT)
Critical Therapeutics, Inc. is developing and commercializing innovative products for respiratory, inflammatory and critical care diseases. The Company owns worldwide rights to two FDA-approved drugs for the prevention and chronic treatment of asthma in patients 12 years of age and older: twice-daily ZYFLO CR™ (zileuton) extended-release tablets and ZYFLO® (zileuton) immediate-release tablets. Critical Therapeutics is working to develop products for acute asthma attacks that lead patients to the emergency room and other urgent care settings. The Company also is developing therapies directed toward the body's inflammatory response. Critical Therapeutics is located in Lexington, Mass.

Company: EyeGate Pharma
Investor Relations Contact: Martin Reynolds
Investor Relations Contact Phone: 978.745.4200 X107
Web: http://www.eyegatepharma.com
Date of Presentation: October 10, 2007 at 3:45 PM
EyeGate Pharma is a privately held, specialty pharmaceutical company pioneering the use of iontophoresis technology to safely and non-invasively deliver therapeutics to the front and back tissues of the eye. The company's lead development program is for severe uveitis.

EyeGate Pharma is addressing the need for an alternative mode of ocular drug delivery because there are safety and efficacy drawbacks posed by current ocular delivery applications, such as eye drops, injections or implants, which are hindered by low bioavailability, collateral toxicities, sight-threatening infections and/or retinal damage.

Company: Hana Biosciences
Ticker Symbol & Exchange: HNAB
Investor Relations Contact: Remy Bernarda
Investor Relations Contact Phone: 650-228-2769
Web: http://www.hanabiosciences.com
Date of Presentation: Wednesday, October 11th at 1:45pm
Hana Biosciences is a development stage biopharmaceutical company engaged in the acquisition, development, and commercialization of products to advance cancer care. The company has an oncology pipeline that includes four cancer therapeutics and one supportive care product candidate. The company's therapeutic products include three compounds that utilize their OPTISOME™ Nanoparticle Technology that include Marqibo® (vincristine), Alocrest™ (vinorelbine) and Brakiva™ (topotecan). Marqibo is currently in a registration study in relapsed acute lymphoblastic leukemia, the rALLy study. Hana's supportive care product is Menadione for the treatment of skin rash associated with the use of epidermal growth factor receptor (EGFR) inhibitors.

Company: Inimex Pharmaceuticals, Inc.
Investor Relations Contact: Dr. John R. North
Investor Relations Contact Phone: 604-225-2251
Web: http://www.inimexpharma.com
Date of Presentation: Wednesday October 10, 2007
Inimex CEO John North is looking forward to presenting at BIO InvestorForum 2007. Inimex is developing a new class of drugs - Innate Defense Regulators - that control infection by modulating the innate defense system without inflammation. (See Nature Biotech April 2007, Scott el al). By acting on the host and not directly on the pathogen, this avoids antibiotic resistance. We're raising a Series B to take our first drug through to phase 2a clinical studies and explore pipeline opportunities arising from this platform. Recent major advances in understanding the molecular target and mechanisms of action of IDRs position Inimex to create substantial value for Series B investors.

Company: Inovio Biomedical Corporation
Ticker Symbol & Exchange: AMEX: INO
Investor Relations Contact: Bernie Hertel
Investor Relations Contact Phone: 858 410 3101
Web: http://www.inovio.com
Date of Presentation: Wednesday, October 10
Inovio is focused on developing multiple DNA-based immunotherapies. Inovio's electroporation-based DNA delivery technology uses brief, controlled electrical pulses to dramatically increase cellular uptake and potency of DNA vaccines and immunotherapies against cancer and chronic infectious diseases. Interim results from three DNA-based immunotherapies in Phase I/II clinical studies have shown safety, tolerability, and heightened immune and/or tumor responses. Inovio's immunotherapy partners include Merck, Wyeth, Vical, University of Southampton, Moffitt Cancer Center, the U.S. Army, National Cancer Institute, and International AIDS Vaccine Initiative.

Company: InterGenetics Incorporated
Investor Relations Contact: Craig Shimasaki, PhD, MBA
Investor Relations Contact Phone: 405-271-1723
Web:
Date of Presentation: 10/11/2007
Dr. Craig Shimasaki, President and CEO of InterGenetics®, a personalized medicine company, will present at the 2007 BIO Investor Forum.

InterGenetics' lead product - OncoVue®, is the first genetic-based breast cancer risk test that incorporates both personal history measures and individualized genetic-based single nucleotide polymorphisms (SNP) to determine an estimate of a woman's breast cancer risk prior to the disease occurrence.

The OncoVue test can provide a genetic based tool for improving clinical estimates of individualized breast cancer risk. Knowing a woman's risk can enable them, along with their physician, to develop an appropriate plan for managing their risk.

Company: Intradigm Corporation
Investor Relations Contact: Stephanie Diaz
Investor Relations Contact Phone: 415-675-7401
Web: http://www.intradigm.com
Date of Presentation: 10-Oct-07
Intradigm is a private biotechnology company developing targeted, systemic RNA interference (RNAi) therapeutics for the treatment of serious diseases with an initial focus on oncology. The company's novel and proprietary RNAi Nanoplex delivery technology is unique in its ability to enable the targeted delivery of RNAi therapeutics to specific tissues through the systemic administration of the drug product. Intradigm's lead oncology product candidate is ICS-238, which is a nanoparticle comprised of multiple siRNAs that target both VEGF (vasular endothelial growth factor) and its receptors.

Company: Manhattan Pharmaceuticals, Inc.
Ticker Symbol & Exchange: AMEX: MHA
Investor Relations Contact: Michelle Carroll;
Investor Relations Contact Phone: 212.582.3950
Date of Presentation: Wednesday, 10 Oct 07
Manhattan Pharmaceuticals, Inc., (Amex: MHA) is a pharmaceutical company that acquires and develops novel, high-value drug candidates primarily for the treatment of dermatologic and immunologic disorders. With a pipeline consisting of four clinical-stage product candidates, Manhattan Pharmaceuticals is developing potential therapeutics for large, underserved patient populations seeking superior treatments for conditions including psoriasis, atopic dermatitis (eczema), head lice, and mastocytosis.

Company: Marshall Edwards Inc
Ticker Symbol & Exchange: MSHL
Investor Relations Contact: John O'Connor
Investor Relations Contact Phone: 612 9976 3148
Web: http://www.marshalledwardsinc.com
Date of Presentation: 11 October, 2007

Marshall Edwards, Inc. is a NASDAQ listed US pharmaceutical company developing a range of anti-cancer therapies.

The company has inlicensed and has access to a portfolio of multiple signal transduction regulators and is undertaking worldwide phase III clinical development of the lead investigational drug phenoxodiol.

Marshall Edwards Inc is also developing a number of related compounds which share phenoxodiol's novel mode of action and have potential for effectiveness across a large number of tumor types. This class of drugs also share a very low toxicity profile.

The company's strategy is to outlicence the drugs at or after registration.

Company: Medivation, Inc.
Ticker Symbol & Exchange: MDVN
Investor Relations Contact: WeissComm Partners
Investor Relations Contact Phone: Daryl Messinger; 415-946-1062
Web: http://www.medivation.com
Date of Presentation: 11-Oct-07
Medivation, Inc. is a San Francisco-based biopharmaceutical company that acquires promising technologies in the late preclinical development phase and develops them quickly and cost-effectively. Dimebon™, the Company's lead product candidate, is an orally-available small molecule that is in clinical testing for the treatment of Alzheimer's and Huntington's diseases—progressive, devastating diseases with limited treatment options. MDV3100, the Company's lead candidate for hormone-refractory prostate cancer, is being evaluated in a Phase 1-2 clinical trial. Medivation intends to build and maintain a portfolio of four to six development programs at all times.

Company: MethylGene Inc.
Ticker Symbol & Exchange: TSX: MYG
Investor Relations Contact: Rhonda Chiger; 917-322-2569
Web: http://www.methylgene.com
Date of Presentation: October 10, 2007 at 4:15 p.m.
MethylGene Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for cancer. MGCD0103, our isotype-selective HDAC inhibitors is in Phase II clinical trials.

Company: Micromet, Inc.
Ticker Symbol & Exchange: NASDAQ: MITI
Investor Relations Contact: Grettel Calvo
Investor Relations Contact Phone: 49 89 89 52 77 110
Web: http://www.micromet-inc.com
Date of Presentation: Oct. 10, 2007, 4:45pm PST
Micromet, Inc. is a biopharmaceutical company focusing on the development of novel, proprietary antibody-based products for cancer, inflammation and autoimmune diseases. Three product candidates currently in clinical trials are:

MT103, a BiTEâ antibody targeting CD19 (MedImmune(a))

MT201, an antibody targeting EpCAM (Merck Serono(a))

D93, an antibody binding cleaved collagen (Tracon(a))

Also, in preclinical development:

MT203, an antibody neutralizing GM-CSF (Nycomed(a))

The BiTEâ antibody product development platform is based on a unique, antibody-based class of drugs that leverages the cytotoxic potential of T cells in the treatment of cancer. For more information go to: http://www.micromet-inc.com .

(a)Development Partner

Company: Momenta Pharmaceuticals
Ticker Symbol & Exchange: MNTA
Investor Relations Contact: Beverly Holley
Investor Relations Contact Phone: (617) 395-5189
Web: http://www.momentapharma.com
Date of Presentation: 10/11/2007
Momenta is a biotechnology company specializing in the detailed structural analysis of complex mixture drugs. Momenta is applying its technology to the development of generic versions of complex drug products as well as to the discovery and development of novel drugs. The Company's most advanced product candidate, M-Enoxaparin, is designed to be a technology-enabled generic version of Lovenox®. Momenta's first novel drug candidate is M118, a rationally engineered anticoagulant specifically designed for acute coronary syndromes. Within the Company's discovery program, it is seeking to discover and develop novel therapeutics by applying its technology to better understand sugars' functions in biological processes, with an initial focus in oncology. Momenta was founded in 2001 based on technology initially developed at MIT.

Company: M's Science Corporation
Investor Relations Contact: Mr. Akihiko Shimauchi;
Web: http://www.m-sci.com
Date of Presentation: October 11, 2:30 P.M.
M's Science Corporation (MSC) is a privately held biopharmaceutical company dedicated to the discovery and development of central nervous system disorders and cancer. MSC is developing two clinical stage products: SA4503, an orally active small molecule for treatment of stroke and depression and HF10, an attenuated herpes simplex virus for treatment of cancer. MSC and its collaborators have conducted a series of Phase 1 and exploratory clinical studies with its two main products in Europe and Japan. MSC is entering into two Phase 2a trials with SA4503 in Europe and a Phase 1/2 trial for HF10 in the United States.

Company: NexBio
Investor Relations Contact: David Wurtman, MD, MBA
Investor Relations Contact Phone: 858-452-2631 ext 108
Web: http://www.nexbio.com
Date of Presentation: 10-Oct-07
NexBio is a 46-person, four year old, San Diego biotechnology company founded to create and commercialize novel, broad-spectrum biopharmaceuticals to prevent and treat current & emerging life-threatening human viral respiratory disease. NexBio has received ~$64M from the NIH for development of Fludase, its lead program, a first-in-class broad-spectrum prophylactic and therapeutic agent for all annual and pandemic variations of influenza including the Avian IFV H5N1 ("Bird Flu"), as well as parainfluenza. TOSAP, a novel, simple, elegant, inexpensive & scalable formulation technology to make dry-powder microspheres invented at NexBio, is being applied to expand the company's pipeline, and is being licensed to partners who wish to formulate their compounds for inhalation. NexBio seeks investors, and seeks corporate partners for its programs.

Company: NuPathe Inc.
Investor Relations Contact: Ezra Felker
Investor Relations Contact Phone: 484-567-0130 ext. 1102
Web: http://www.nupathe.com
Date of Presentation: 10-Oct
NuPathe Inc. is a privately held specialty pharmaceutical company focused on neurology and psychiatry. NuPathe identifies patient needs, then finds the best solutions.

Nupathe's lead product, NP101, uses SmartRelief™, the company's novel, transdermal patch technology to deliver sumatriptan, a widely - used therapy for the treatment of acute migraine. Pending regulatory approval, NP 101 would be the first ever migraine treatment using a transdermal patch delivery system. Phase 1 clinical results for NP 101 have thus far demonstrated rapid delivery of migraine medication and improved pharmacokinetics compared to current standard of care. NP101 is entering Phase III Clinical Trails by the end of 2007.

Company: Nventa Biopharmaceuticals Corporation
Ticker Symbol & Exchange: TSX:NVN
Investor Relations Contact: Donna Slade
Investor Relations Contact Phone: 858 202-4945
Web: http://www.nventacorp.com
Date of Presentation: October 10 @ 1:15 pm
Nventa Biopharmaceuticals Corporation is developing innovative therapeutics for the treatment of viral infections and cancer, with a focus on diseases caused by the human papillomavirus (HPV).

The Company's lead initiative is the development of HspE7, a therapeutic vaccine for the possible treatment of patients with cervical dysplasia, genital warts and recurrent respiratory papillomatosis.

Nventa has developed a unique, proprietary technology platform that harnesses the immunostimulatory powers of heat shock proteins to trigger the immune system to recognize specific diseases. Its CoVal™ fusions use recombinant DNA technology to fuse, or covalently link, a heat shock protein with a protein antigen to create a single hybrid protein, also referred to as a therapeutic vaccine or immunotherapeutic, designed to recognize that antigen.

Company: OCULUS INNOVATIVE SCIENCES
Ticker Symbol & Exchange: (NASDAQ: OCLS)
Investor Relations Contact: Sara Ephraim, The Ruth Group
Investor Relations Contact Phone: 646-536-7002
Web: http://www.oculusis.com
Date of Presentation: 10/11/2007 13:30
Oculus Innovative Sciences is a biopharmaceutical company that develops, manufactures and markets a family of products based upon the Microcyn® Technology platform, which is intended to help prevent and treat infections in chronic and acute wounds. The Microcyn Technology platform is a controlled slow-release solution containing active chlorine and other gases resulting in a biocompatible technology to treat a wide range of pathogens, including antibiotic-resistant strains of bacteria, viruses, fungi and spores. The technology has demonstrated significant wound healing in chronic and acute wounds. It has been commercialized outside of the U.S. for the treatment of infected wounds. It is currently under evaluation for the treatment of mildly infected diabetic ulcers in the U.S.

Company: Oncolytics Biotech Inc.
Ticker Symbol & Exchange: TSX:ONC, NASDAQ:ONCY
Investor Relations Contact: Cathy Ward
Investor Relations Contact Phone: 403.670.7370
Web: http://www.oncolyticsbiotech.com
Date of Presentation: 11-Oct-07
Oncolytics Biotech Inc. was formed in 1998 to develop its proprietary product, REOLYSIN®, as a potential therapeutic for a wide variety of human cancers.

Oncolytics has completed six clinical trials with REOLYSIN® in Canada, the U.K. and the U.S. and is currently conducting seven Phase I or Phase II REOLYSIN® trials in the U.K. and the U.S.

The current clinical program includes local or systemic delivery of REOLYSIN® as a monotherapy, and local or systemic delivery of REOLYSIN® in combination with radiation or chemotherapy for patients with advanced cancers

Company: Osteologix, Inc
Ticker Symbol & Exchange: OTCBB: OLGX
Investor Relations Contact: Baxter Phillips, III
Investor Relations Contact Phone: 804.754.6970
Web: http://www.osteologix.com
Date of Presentation: 10-Oct-07
Osteologix (OLGX) is a specialty pharmaceutical company committed to developing innovative therapies for the treatment and prevention of musculoskeletal diseases. It is our vision to improve the health of those afflicted with musculoskeletal diseases such as osteoporosis. We partner with the healthcare community to apply new scientific information and clinical data to the development of products that improve patient care in a safe and ethical manner. Osteologix's lead product candidate, NB S101, is a novel once daily tablet for the treatment and prevention of osteoporosis. NB S101 helps to build bone in a manner similar to the body's own natural process by gently rebalancing bone metabolism in a way that favors strong bone development.

Company: Peregrine Pharmaceuticals, Inc.
Ticker Symbol & Exchange: PPHM (NASDAQ)
Investor Relations Contact: GendelLindheim BioCom Partners
Investor Relations Contact Phone: Barbara Lindheim; 800 987-8256
Web: http://www.peregrineinc.com
Date of Presentation: October 10, 2007 - 3:45pm (PDT)
Peregrine Pharmaceuticals is developing targeted therapies for the treatment of cancer and hepatitis C virus (HCV) infection. Its three clinical programs include lead oncology candidates bavituximab for solid tumors and Cotara® for brain cancer. Both showed positive signs of anti-tumor activity in earlier studies and are now advancing through ongoing and planned Phase II efficacy trials. Bavituximab also showed promising signs of anti-viral activity in Phase I HCV trials and is currently being studied in patients co-infected with HCV and HIV. Wholly owned subsidiary Avid Bioservices provides bio-manufacturing services for Peregrine and outside customers. For additional information, visit http://www.peregrineinc.com .

Company: Phase Bioscience, Inc.
Web: http://www.phasebio.com
Date of Presentation: 10/11/2007 15:00
Phase Bioscience, Inc.(PhaseBio), located in Research Triangle Park, NC, is a privately held biopharmaceutical company molded around an innovative set of technologies that provide new solutions to delivery, production and purification of both protein-based therapeutics and small molecules. Our proprietary Elastin-Like Peptide (ELP) technology enables the Company and its partners to efficiently express and purify proteins and dramatically improve their pharmaceutical attributes. The company's deltaPhase® process for biologic purification eliminates expensive chromatography and ELP mediated drug delivery can turn a good drug into a great one.

Company: Poniard Pharmaceuticals
Ticker Symbol & Exchange: NASDAQ: PARD
Investor Relations Contact: Julie Rathbun
Investor Relations Contact Phone: 650-583-3774 x517
Web: www.poniard.com
Date of Presentation: Wednesday, Oct. 10th
Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company's lead product candidate, is a new generation platinum therapy with an improved safety profile. Picoplatin is designed to overcome and prevent platinum resistance associated with chemotherapy in solid tumors. Intravenous picoplatin is currently being studied in clinical trials for the treatment of small cell lung, colorectal and hormone-refractory prostate cancer, and oral picoplatin is in a clinical trial in solid tumors. For more information, visit www.poniard.com.

Company: Protherics PLC
Ticker Symbol & Exchange: LSE: PTI, NASDAQ: PTIL
Investor Relations Contact: Nick Staples
Investor Relations Contact Phone: 44 (0)20 7246 9950 or 44 (0)7919480510
Web: http://www.protherics.com
Date of Presentation: 11:30 AM on Thursday, October 11, 2007
Protherics PLC is a leading biopharmaceutical company focused on the development, manufacture and marketing of specialized products for critical care and cancer.

Protherics has developed and manufactures two biologics for critical care which are FDA approved and currently sold in the US: CroFab™, a pit viper antivenom and DigiFab™, a digoxin antidote. The Company's strategy is to use the revenues generated from its marketed and out-licensed products to help fund the advancement of its broad, late stage pipeline.

Protherics has two major development opportunities in its critical care portfolio. CytoFab™ is being developed by AstraZeneca for the treatment of severe sepsis and Digoxin Immune Fabs for the treatment of pre-eclampsia. Protherics also has a pipeline of four novel cancer products in clinical development.

With headquarters in London, the Company has approximately 270 employees in the UK, US and Australia. For further information please visit www.protherics.com

Company: RegeneRx Biopharmaceuticals Inc.
Ticker Symbol & Exchange: RGN : AMEX
Investor Relations Contact: J.J. Finkelstein
Web: http://www.regenerx.com
Date of Presentation: 10/11/2007
RegeneRx is a biopharmaceutical company developing thymosin beta 4 (Tb4) as a platform technology for the treatment of a variety of human diseases involving tissue/organ protection and repair. The company is conducting 3 Phase 2 clinical trials for the treatment of acute and chronic dermal wounds, a Phase 2 trial for ophthalmic wound healing, and a Phase 1 trial for repair of the myocardium after acute myocardial infarction. RegeneRx holds an exclusive world-wide license from the NIH for certain components of its technology.

Company: SensiGen LLC
Investor Relations Contact: Eileen Wu
Investor Relations Contact Phone: 215-966-6047
Web: http://www.sensigen.com
Date of Presentation: Thursday, October 11th at 3 PM

SensiGen is a development stage biotechnology company focused on gene-based molecular diagnostics. It develops advanced technologies for early detection of diseases to improve the standard of care and reduce healthcare costs. To date, SensiGen has applied its technology platform to the development of proprietary diagnostic tests for human papillomavirus (HPV), the primary cause of cervical cancer, to chronic kidney disease (CKD), a serious condition associated with diabetes, hypertension, and lupus, and to diagnostic tests for lupus and IBD. These proprietary diagnostic assays offer dramatic improvements over current methods in the diagnosis and treatment monitoring of disease.

Company: SuperGen, Inc.
Ticker Symbol & Exchange: NASDAQ: SUPG
Investor Relations Contact: Mary M. Vegh
Investor Relations Contact Phone: 925.560.2845
Web: http://www.supergen.com .
Date of Presentation: October 10, 2007 at 1:45 p.m. PDT
Based in Dublin, Calif., SuperGen, Inc. is a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies. SuperGen is developing a number of therapeutic anticancer products focused on kinase and cell signaling inhibitors and DNA methyltransferase inhibitors. For more information about SuperGen, please visit http://www.supergen.com.

Company: Targacept
Ticker Symbol & Exchange: Nasdaq: TRGT
Investor Relations Contact: Alan Musso
Investor Relations Contact Phone: (336) 480-2100
Web: http://www.targacept.com
Date of Presentation: 10:45 am (J. Donald deBethizy, PhD)
Targacept (NASDAQ: TRGT) is a clinical-stage biopharmaceutical company that discovers and develops NNR Therapeutics™, a new class of drugs for the treatment of central nervous system diseases and disorders. Targacept's product candidates selectively modulate neuronal nicotinic receptors (NNRs) that serve as key regulators of the nervous system to promote therapeutic effects and limit adverse side effects. Targacept has product candidates in development for Alzheimer's disease and cognitive deficits in schizophrenia, pain, and depression and anxiety disorders, as well as multiple preclinical programs. Targacept has strategic alliances with AstraZeneca and GlaxoSmithKline.

Company: Target Discovery, Inc.
Investor Relations Contact: Jeff Peterson, CEO
Investor Relations Contact Phone: 650-812-8121
Web: http://www.targetdiscovery.com
Date of Presentation: 10/10/2007
Target Discovery is developing the next generation of clinical diagnostics, offering higher value molecular insights for the diagnosis and management of disease. TDI accesses the "missing link" in biomarkers: protein isoform diagnostics (Isonostics™), to better guide therapeutic choices for cancer and lower the overall costs of cancer treatment. TDI's lead program is ovarian cancer treatment guidance diagnostics (in collaboration with MD Anderson Cancer Center). The company engages in funded collaborations with partners, for application of its unique isoform-level technologies in other disease areas and in theranostic applications (diagnostic testing to select or disqualify patients for a specific drug therapy).

Company: Vasogen Inc.
Ticker Symbol & Exchange: VSGN:NASDAQ
Investor Relations Contact: Glenn Neumann
Investor Relations Contact Phone: 905-817-2004
Web: http://www.vasogen.com
Date of Presentation: 11-Oct-07
Vasogen is a biotechnology company engaged in the research and commercial development of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. Vasogen's Celacade™ technology designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation - is in late-stage development for the treatment of chronic heart failure and has received European regulatory approval under the CE Mark for this indication. VP025, a lead drug candidate from the new class of drugs Vasogen is developing for the treatment of certain neuro-inflammatory disorders, is entering phase II development.

Company: ViaCell, Inc.
Ticker Symbol & Exchange: Nasdaq: VIAC
Investor Relations Contact: Justine Koenigsberg
Investor Relations Contact Phone: 617-914-3494
Web: http://www.viacellinc.com
Date of Presentation: 10-Oct-07
ViaCell markets ViaCord, a product offering through which families can preserve their baby's umbilical cord blood at the time of birth for possible future medical use in treating over 40 diseases including certain blood cancers and genetic diseases. The Company is also developing ViaCyte, a product candidate being studied for its potential to broaden reproductive choices for women through the cryopreservation of human unfertilized eggs. ViaCell conducts research and development primarily to investigate other potential therapeutic uses of umbilical cord blood-derived stem cells. Its pipeline is focused in the areas of cancer, cardiac disease, and diabetes.

Company: ZIOPHARM Oncology, Inc.
Ticker Symbol & Exchange: NASDAQ:ZIOP
Investor Relations Contact: Suzanne McKenna
Investor Relations Contact Phone: 646-214-0703
Web: http://www.ziopharm.com
Date of Presentation: 10-Oct-07
ZIOPHARM Oncology is a biopharmaceutical company engaged in the development and commercialization of a diverse, risk-sensitive portfolio of in-licensed cancer drugs to address unmet medical needs. The Company applies new insights from molecular and cancer biology to understand the efficacy and safety limitations of approved and developmental cancer therapies and identifies proprietary and related molecules for better patient treatment.